Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection | Zendy

David A. Cooper | Zendy; Roy T. Steigbigel | Zendy; José M. Gatell | Zendy; Jürgen K. Rockstroh | Zendy; Christine Katlama | Zendy; Patrick Yéni | Zendy; Adriano Lazzarin | Zendy; Bonaventura Clotet | Zendy; Princy Kumar | Zendy; Joseph Eron | Zendy; Mauro Schechter | Zendy; Martin Markowitz | Zendy; Mona Loutfy | Zendy; Jeffrey L. Lennox | Zendy; Jing Zhao | Zendy; Joshua Chen | Zendy; Desmon̄d Ryan | Zendy; Rand R. Rhodes | Zendy; John A. Killar | Zendy; Lucinda R. Gilde | Zendy; Kim M. Strohmaier | Zendy; Anne R. Meibohm | Zendy; Michael D. Miller | Zendy; Daria J. Hazuda | Zendy; Michael L. Nessly | Zendy; Mark J. DiNubile | Zendy; Robin Isaacs | Zendy; Hedy Teppler | Zendy; Bach-Yen Nguyen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

Author(s) -

David A. Cooper,

Roy T. Steigbigel,

José M. Gatell,

Jürgen K. Rockstroh,

Christine Katlama,

Patrick Yéni,

Adriano Lazzarin,

Bonaventura Clotet,

Princy Kumar,

Joseph Eron,

Mauro Schechter,

Martin Markowitz,

Mona Loutfy,

Jeffrey L. Lennox,

Jing Zhao,

Joshua Chen,

Desmon̄d Ryan,

Rand R. Rhodes,

John A. Killar,

Lucinda R. Gilde,

Kim M. Strohmaier,

Anne R. Meibohm,

Michael D. Miller,

Daria J. Hazuda,

Michael L. Nessly,

Mark J. DiNubile,

Robin Isaacs,

Hedy Teppler,

Bach-Yen Nguyen

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0708978

Subject(s) - raltegravir , medicine , virology , human immunodeficiency virus (hiv) , drug resistance , integrase inhibitor , antiretroviral drug , hiv drug resistance , antiretroviral therapy , clinical trial , viral load , biology , microbiology and biotechnology

We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research